Prospective study to test the effectiveness of surgery for improving function of swallowing in head and neck cancer patients using high-resolution manometry - Prospective study to test the effectiveness of surgery for improving function of swallowing in head and neck cancer patients using high-resolution manometry

Start Date01 Apr 2024

Sponsor / Collaborator

Japanese Foundation for Cancer Research

JPRN-UMIN000050925 / RecruitingIIT

An observational study of the safety and efficacy of nivolumab as adjuvant treatment for esophageal cancer using the Comprehensive Registry of Esophageal Cancer in the National Clinical Database. - An observational study of the safety and efficacy of adjuvant nivolumab therapy for esophageal cancer.

Start Date01 Jan 2023

Sponsor / Collaborator

Japanese Foundation for Cancer Research

JPRN-UMIN000048382 / CompletedIIT

Development and Validation of a Predictive Nomogram of Disease Recurrence after Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment - Development and Validation of a Predictive Nomogram of Disease Recurrence after Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment

Start Date17 Sep 2021

Sponsor / Collaborator

Japanese Foundation for Cancer Research

100 Clinical Results associated with Japanese Foundation for Cancer Research

0 Patents (Medical) associated with Japanese Foundation for Cancer Research

6,203

Literatures (Medical) associated with Japanese Foundation for Cancer Research

31 Dec 2024·OncoImmunology

Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes

Article

Author: Nakamura, Yusuke ; Tate, Tomohiro ; Kitano, Shigehisa ; Kiyotani, Kazuma ; Okamura, Kazumi ; Wang, Lifang ; Yamashita, Makiko ; Nagayama, Satoshi ; Matsumoto, Saki ; Takamatsu, Manabu

TCRαβ+ CD4- CD8- double-negative T (DNT) cells are minor populations in peripheral blood, and their roles have mostly been discussed in inflammation and autoimmunity. However, the functions of DNT cells in tumor microenvironment remain to be elucidated. We investigated their characteristics, possible origins and functions in colorectal cancer tissues as well as their corresponding tumor-draining lymph nodes. We found a significant enrichment of DNT cells in tumor tissues compared with their corresponding lymph nodes, especially in tumors with lower T cell infiltration. T cell receptor (TCR) sequence analysis of CD4+ T, CD8+ T and DNT cells indicated that TCR sequences detected in DNT cells were found in CD8+ T cells, but rarely in CD4+ T cells, suggesting that a part of DNT cells was likely to be originated from CD8+ T cells. Through a single-cell transcriptomic analysis of DNT cells, we found that a DNT cell cluster, which showed similar phenotypes to central memory CD8+ T cells with low expression of effector and exhaustion markers, revealed some specific gene expression patterns, including higher GZMK expression. Moreover, in flow cytometry analysis, we found that DNT cells lost production of cytotoxic mediators. These findings imply that DNT cells might function as negative regulators of anti-tumor immune responses in tumor microenvironment.

01 Nov 2024·Cancer Letters

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer

Article

Author: Utsumi, Takahiro ; Koike, Sumie ; Uchibori, Ken ; Kondo, Nobuyuki ; Yanagitani, Noriko ; Nishio, Makoto ; Wei, Xinzhao ; Takemoto, Ai ; Katayama, Ryohei ; Takagi, Satoshi

Recently approved RET tyrosine kinase inhibitors (TKIs) have shown promising therapeutic effects against RET-rearranged non-small cell lung cancer (NSCLC) or RET-mutated thyroid cancer. However, resistance develops, limiting long-term efficacy. Although many RET-TKI resistance mechanisms, such as secondary mutations in RET or activation of bypass pathways, are known, some primary or acquired resistance mechanisms are unclear. Here, human genome-wide CRISPR/Cas9 screening was performed to identify genes related to drug-tolerant persister cells. Patient-derived cells with RET-fusion were introduced genome-wide sgRNA library and treated with RET-TKI for 9 days, resulting in the discovery of several candidate genes. Knockout of MED12 or MIG6 significantly increased residual drug-tolerant persister cells under RET-TKI treatment. MIG6 loss induced significant EGFR activation even with low concentrations of EGFR ligands and led to resistance to RET-TKIs. EGFR inhibition with afatinib or cetuximab in combination with RET TKIs was effective in addressing drug persistence. By contrast, a KIF5B-RET positive cells established from a RET-rearranged NSCLC patient, showed significant resistance to RET-TKIs and high dependence on EGFR bypass signaling. Consistently, knocking out EGFR or RET led to high sensitivity to RET or EGFR inhibitor respectively. Here, we have provided a comprehensive analysis of adaptive and acquired resistance against RET-rearranged NSCLC.

01 Nov 2024·Gut

W-eCura score versus eCura system: comparison in the external cohort is required

Letter

Author: Ogata, Yohei ; Masamune, Atsushi ; Koike, Tomoyuki ; Hatta, Waku ; Gotoda, Takuji

News (Medical) associated with Japanese Foundation for Cancer Research

08 Dec 2022

·www.prnewswire.com

Japanese Healthcare Startup Ubie, Inc. Closes Extended Series C Round at $45 million, Establishes Subsidiary in NY

TOKYO, Dec. 8, 2022 /PRNewswire/ -- Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that market. To date, Ubie has raised $76 million in total. Image: The extension round money was raised from SOGO MEDICAL CO., LTD., AAIC Investment Pte. Ltd., Japan Impact Investment II Limited Partnership, and Rakuten Capital, while loans extended from the Shoko Chukin Bank, Ltd., Japan Finance Corporation, and Mizuho Bank, Ltd. Previous press release about Series C: Purpose of Series C funding Ubie, with the mission of "guiding people to appropriate medical care with technology," is one of the few companies in the world having direct contact with both patients and medical institutions. With AI as its core technology, the company provides AI symptom checker Ubie ( ) as the gateway to medical care. It will also focus on expanding its business to the U.S. in order to apply the technology it has developed in Japan, one of the leading countries in the medical field. Subsidiary set up in NY Leveraging the Series C funding, Ubie established a local subsidiary in New York on October 4, 2022. This is the second overseas corporation following Singapore. The decision follows the fact that the number of users has been increasing steadily since the release of the AI symptom checker in April 2022 in the U.S. The establishment of the local subsidiary will further strengthen the partnership with U.S. pharmaceutical companies, as well as the products, including hiring local people in the U.S. Address: 1460 Broadway, New York, NY 10036 Participation of new board member Ryusuke Shigetomi, Chairman and Representative Director of Blackstone Group Japan, was appointed as a Ubie board member as an outside director to strengthen the company's management structure and governance. About Ryusuke Shigetomi: In 1984, he graduated from the University of Tokyo, Faculty of Law, and joined Industrial Bank of Japan. In 2000, he joined Morgan Stanley, where he was responsible for the Telecom, Media, and Technology Group in Japan and assisted in the execution of various large-scale financing projects and M&A transactions for 22 years. In 2021, he joined the Blackstone Group, where he served as Chairman and Representative Director and was involved in investment and fundraising activities in Japan. SOURCE Ubie, Inc.

Executive Change

06 Dec 2022

·www.sciencedaily.com

'Unwinding' chromosomes: A unique perspective on determinants of chromosomal width

Mitotic chromosomes are pivotal for the inheritance of genetic material. Now, it is already known that chromosomes vary in dimensions among organisms. But what governs mitotic chromosomal size and degree of DNA compaction? Scientists investigated mitotic chromosome formation to find answers and have revealed that within a species, the chromosomal arm length determines its width. These new insights challenge the current perspectives of chromosome formation. Chromosomes are a highly condensed form of DNA and are crucial for cell division. During mitosis, chromosomes ensure that the genetic material is equally divided among the daughter cells. Interestingly, the dimensions and degree of DNA condensation in mitotic chromosomes vary from organism to organism. How this is regulated -- i.e., what factor governs mitotic chromosomal formation and dimensions -- remains a mystery. A team of researchers led by Dr. Yasutaka Kakui from Waseda Institute for Advanced Study, Waseda University; Frank Uhlmann at the Chromosome Segregation Laboratory, The Francis Crick Institute; and Toru Hirota, from the Division of Experimental Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, set out to decode this enigma. How did it all start? For Kakui, it was his fascination for chromosomes that motivated him to take up this research. "How is genomic DNA stored within cells? This is an ancient, unsolved question. To expand our knowledge of how cells accurately pass on genetic information to successive generations, we need to understand the molecular basis for chromosome formation." And that is what drove this study, the findings of which have been published in Cell Reports. During mitosis, DNA undergoes significant compaction to form chromosomes. A large protein ring complex called condensin plays a key role in the compaction process. It binds at specific sites on DNA and compresses it by forming loops. So, scientists know that condensin is crucial for DNA compaction, which is closely related to chromosomal dimensions -- with thicker chromosomes being more compacted. They also know that the pattern of condensin-binding sites is species-specific. But the exact role of condensin and chromatin contacts in determining chromosomal dimensions is, as yet, unclear. The researchers explored various facets of condensin and chromatin contacts to address the questions at hand. They employed Hi-C and super-resolution microscopy to analyze the correlation between mitotic chromatin contacts and chromosomal arm length in both budding and fission yeasts, S. cerevisiae and S. pombe, respectively. Conclusive evidence was found indicating that the distance between chromatin contacts is directly proportional to arm length in both interphase and mitosis. Hence, shorter arms have short range contacts and longer arms have long range contacts. This was found to be species-specific. Now, longer distances of chromatin contacts lead to larger chromatin loops, both of which are indicators of wider chromosomal arms. The authors thus investigated both budding and fission yeasts to conclude that within a species, longer chromosomal arms were always wider. Motivated by the successful observation in the yeasts, they extended their study to human cells, to find the same correlations. "We made the unexpected discovery that longer chromosomal arms are always thicker throughout eukaryotic species, which helps us understand how mitotic chromosomes form during cell divisions," explains Kakui. Their study would be the first to conclusively establish that chromosomal arm length determines mitotic chromosome width. This study has provided unique insights into mitotic chromosomal structure that challenge the current perspectives on mitotic chromosome formation. Kakui summarizes, "Our findings would open a novel way to avoid chromosome miscarriage, a probable cause for the formation of cancer cells and/or birth defects such as Down syndrome, through controlling mitotic chromosome structure. This can potentially change medical treatments for cancer therapy and/or fertility treatments."

02 Nov 2022

·www.prnewswire.com

Mono Vaccine Market to Grow by USD 2.8 Bn, Meningococcal Vaccine to be Largest Revenue-generating Type Segment - Technavio

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- The mono-vaccine market is expected to grow by USD 2.8 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.16% during the forecast period, according to Technavio. This growth can be attributed to the increase in the pediatric population. However, rising antimicrobial resistance can hamper the growth of the market during the next few years. View a comprehensive report summary that describes the market size and forecast along with the research methodology. The FREE sample report is available in PDF format Continue Reading Technavio has announced its latest market research report titled Global Mono Vaccine Market 2022-2026 Mono Vaccine Market 2022-2026: Scope The mono-vaccine market report covers the following areas: Mono Vaccine Market size Mono Vaccine Market trends Mono Vaccine Market industry analysis Subscribe to our "Lite Plan" billed annually at USD 5000 enables you to download 5 reports and view 100 reports per month Mono Vaccine Market 2022-2026: Segmentation Type Meningococcal Vaccine Japanese Encephalitis Vaccine Hepatitis Vaccine Yellow Fever Vaccine Others The mono-vaccine market share growth in the Meningococcal Vaccine segment will be significant during the forecast period. Meningococcal meningitis is a type of meningitis caused by the Neisseria meningitides bacteria, which can be transmitted from an infected person through direct contact with droplets from the throat or respiratory secretions. Asymptomatic carriers are also capable of transmitting the infection. Such prevalence of meningococcal disease across the globe is expected to fuel the growth of the global mono-vaccine market during the forecast period. Geography North America Europe Asia Rest Of World (ROW) 36% of the market's growth will originate from North America during the forecast period. The US is the key market for the mono-vaccine market in North America. The increase in the pediatric population will facilitate the mono-vaccine market growth in North America over the forecast period. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report Mono Vaccine Market 2022-2026: Vendor Analysis We provide a detailed analysis of around 25 vendors operating in the Mono Vaccine Market, including AstraZeneca Plc, Aurobindo Pharma Ltd., Bavarian Nordic AS, China National Pharmaceutical Group Corp., Dynavax Technologies Corp., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Valneva SE, and VBI Vaccines Inc. The key offerings of some of these vendors are listed below: Shenzhen Kangtai Biological Products Co. Ltd. - The company, Shenzhen Kangtai Biological Products Co. Ltd. offers a mono vaccine, namely the SARS-COV 2 Vaccine. AstraZeneca Plc - The company offers mono-vaccine namely COVAX. Aurobindo Pharma Ltd. - Under this segment, the company manufactures generic pharmaceuticals and active pharmaceutical ingredients. Sanofi SA - The company offers mono vaccine through its subsidiary China National Biotec Group. Dynavax Technologies Corp. - The company offers mono-vaccine namely Heplisav B. This report provides a full list of key vendors, their strategies, and latest developments. Buy Now to gain access to exclusive vendor information Mono Vaccine Market 2022-2026: Key Highlights CAGR of the market during the forecast period 2022-2026 Detailed information on factors that will assist mono-vaccine market growth during the next five years Estimation of the mono vaccine market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the mono-vaccine market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of mono-vaccine market vendors Related Reports: Travel Vaccines Market by Disease Type and Geography – Forecast and Analysis 2022-2026: The travel vaccines market share is expected to increase to USD 2.44 billion from 2021 to 2026. Tetanus Toxoid Vaccine Market by Age Group and Geography – Forecast and Analysis 2022-2026: The tetanus toxoid vaccine market share is expected to increase by USD 1.17 billion from 2021 to 2026. Table Of Contents : 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market Definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Meningococcal Vaccine - Market size and forecast 2021-2026 Exhibit 28: Chart on Meningococcal Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Meningococcal Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Meningococcal Vaccine - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Meningococcal Vaccine - Year-over-year growth 2021-2026 (%) 5.4 Japanese Encephalitis Vaccine - Market size and forecast 2021-2026 Exhibit 32: Chart on Japanese Encephalitis Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Japanese Encephalitis Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Japanese Encephalitis Vaccine - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Japanese Encephalitis Vaccine - Year-over-year growth 2021-2026 (%) 5.5 Hepatitis Vaccine - Market size and forecast 2021-2026 Exhibit 36: Chart on Hepatitis Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Hepatitis Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Hepatitis Vaccine - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Hepatitis Vaccine - Year-over-year growth 2021-2026 (%) 5.6 Yellow Fever Vaccine - Market size and forecast 2021-2026 Exhibit 40: Chart on Yellow Fever Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 41: Data Table on Yellow Fever Vaccine - Market size and forecast 2021-2026 ($ million) Exhibit 42: Chart on Yellow Fever Vaccine - Year-over-year growth 2021-2026 (%) Exhibit 43: Data Table on Yellow Fever Vaccine - Year-over-year growth 2021-2026 (%) 5.7 Others - Market size and forecast 2021-2026 Exhibit 44: Chart on Others - Market size and forecast 2021-2026 ($ million) Exhibit 45: Data Table on Others - Market size and forecast 2021-2026 ($ million) Exhibit 46: Chart on Others - Year-over-year growth 2021-2026 (%) Exhibit 47: Data Table on Others - Year-over-year growth 2021-2026 (%) 5.8 Market opportunity by Type Exhibit 48: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 49: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 50: Chart on Market share by geography 2021-2026 (%) Exhibit 51: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 52: Chart on Geographic comparison Exhibit 53: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 54: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 62: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 66: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 France - Market size and forecast 2021-2026 Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million) Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million) Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%) Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 86: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 87: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 88: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 89: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 90: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 91: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 92: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 93: Overview on factors of disruption 9.4 Industry risks Exhibit 94: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 95: Vendors covered 10.2 Market positioning of vendors Exhibit 96: Matrix on vendor position and classification 10.3 AstraZeneca Plc Exhibit 97: AstraZeneca Plc - Overview Exhibit 98: AstraZeneca Plc - Product / Service Exhibit 99: AstraZeneca Plc - Key news Exhibit 100: AstraZeneca Plc - Key offerings 10.4 China National Pharmaceutical Group Corp. Exhibit 101: China National Pharmaceutical Group Corp. - Overview Exhibit 102: China National Pharmaceutical Group Corp. - Product / Service Exhibit 103: China National Pharmaceutical Group Corp. - Key offerings 10.5 Dynavax Technologies Corp. Exhibit 104: Dynavax Technologies Corp. - Overview Exhibit 105: Dynavax Technologies Corp. - Product / Service Exhibit 106: Dynavax Technologies Corp. - Key news Exhibit 107: Dynavax Technologies Corp. - Key offerings 10.6 GlaxoSmithKline Plc Exhibit 108: GlaxoSmithKline Plc - Overview Exhibit 109: GlaxoSmithKline Plc - Business segments Exhibit 110: GlaxoSmithKline Plc - Key offerings Exhibit 111: GlaxoSmithKline Plc - Segment focus 10.7 Merck and Co. Inc. Exhibit 112: Merck and Co. Inc. - Overview Exhibit 113: Merck and Co. Inc. - Business segments Exhibit 114: Merck and Co. Inc. - Key news Exhibit 115: Merck and Co. Inc. - Key offerings Exhibit 116: Merck and Co. Inc. - Segment focus 10.8 Moderna Inc. Exhibit 117: Moderna Inc. - Overview Exhibit 118: Moderna Inc. - Business segments Exhibit 119: Moderna Inc. - Key offerings Exhibit 120: Moderna Inc. - Segment focus 10.9 Pfizer Inc. Exhibit 121: Pfizer Inc. - Overview Exhibit 122: Pfizer Inc. - Product / Service Exhibit 123: Pfizer Inc. - Key news Exhibit 124: Pfizer Inc. - Key offerings 10.10 Sanofi SA Exhibit 125: Sanofi SA - Overview Exhibit 126: Sanofi SA - Business segments Exhibit 127: Sanofi SA - Key news Exhibit 128: Sanofi SA - Key offerings Exhibit 129: Sanofi SA - Segment focus 10.11 Serum Institute of India Pvt. Ltd. Exhibit 130: Serum Institute of India Pvt. Ltd. - Overview Exhibit 131: Serum Institute of India Pvt. Ltd. - Product / Service Exhibit 132: Serum Institute of India Pvt. Ltd. - Key offerings 10.12 Shenzhen Kangtai Biological Products Co. Ltd. Exhibit 133: Shenzhen Kangtai Biological Products Co. Ltd. - Overview Exhibit 134: Shenzhen Kangtai Biological Products Co. Ltd. - Product / Service Exhibit 135: Shenzhen Kangtai Biological Products Co. Ltd. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 136: Inclusions checklist Exhibit 137: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 138: Currency conversion rates for US$ 11.4 Research methodology Exhibit 139: Research methodology Exhibit 140: Validation techniques employed for market sizing Exhibit 141: Information sources 11.5 List of abbreviations Exhibit 142: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Vaccine

100 Deals associated with Japanese Foundation for Cancer Research

100 Translational Medicine associated with Japanese Foundation for Cancer Research

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KM3168 ( IGF-1 )	Intestinal Polyposis More	Preclinical
KM-1468 ( IGF-2 )	Intestinal Polyposis More	Preclinical
A-83-01 ( ALK4 x ALK5 x ALK7 )	Neoplasms More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis